Type 2 diabetes mellitus (T2DM) and obesity are metabolic disorders characterized by
excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists …

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1)
exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion …

Short-chain fatty acids (SCFAs) are the main metabolites produced by bacterial fermentation
of dietary fibre in the gastrointestinal tract. The absorption of SCFAs is mediated by substrate …

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) exert anti-inflammatory effects
relevant to the chronic complications of type 2 diabetes. Although GLP-1RAs attenuate T cell …

Incretin hormones, principally glucose-dependent insulinotropic polypeptide (GIP) and
glucagon-like peptide-1 (GLP-1), potentiate meal-stimulated insulin secretion through direct …

The human gastrointestinal tract is populated with a diverse microbial community. The vast
genetic and metabolic potential of the gut microbiome underpins its ubiquity in nearly every …

The gastrointestinal tract is home to the largest microbial population in the human body. The
gut microbiota plays significant roles in the development of the gut immune system and has …

Objectives Glucagon-like peptide-1 receptor (GLP-1R) agonists reduce the rates of major
cardiovascular events, including myocardial infarction in people with type 2 diabetes, and …

Abstract In the United States, adolescent obesity is a growing epidemic associated with
maladaptive executive functioning. Likewise, data link the microbiome to obesity. Emerging …

Inulin, a commonly used dietary fiber supplement, is capable of modulating the gut
microbiome. Chronic inflammation resulting from metabolic abnormalities and gut flora …